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The worldwide hepatitis and HIV/AIDS epidemics are overwhelming.Globally, 200 million people -- more than three percent of the world’s
population -- are infected with hepatitis C, and nearly 33 million people are
reported to be living with HIV.1, 2  
The global situation often overshadows the
need to also address these diseases domestically.
 An estimated 3.2 million Americans have
chronic hepatitis C infections, costing the
country an estimated $15 billion annually in
health care costs.3, 4 Approximately 8,000 -
10,000 people die every year from hepatitis C
related liver disease.5 It is the leading cause
of cirrhosis and liver cancer and the most
common reason for liver transplantation in
the United States.  In 2006, there were ap-
proximately 19,000 new hepatitis C virus in-
fections in this country.6 This number is
believed to be conservative, since many
Americans are unaware they are infected.7
 An additional 800,000 to 1.4 million peo-
ple are estimated to have chronic viral
hepatitis B infection in the United States.8
This number is also likely to be an under-
estimate because most people who are in-
fected do not know they have the disease
until they show symptoms of illness.  
 An estimated 1.0 to 1.2  million Americans
are living with Human Immunodeficiency
Virus (HIV) and/or Acquired Immuno -
deficiency Syndrome (AIDS).9 There are
an estimated 56,300 new cases of HIV
diagnosed in this country every year.10
More than 583,000 Americans have died
of AIDS since 1981.11 In Fiscal Year 2007,
total federal spending on HIV/AIDS-
related medical care, research, prevention,
and other activities in the United States
was $23.3 billion.12  
One of the most effective, scientifically-based
methods for reducing these diseases -- needle
exchange programs -- has become embroiled
in politics, based on some long-held misper-
ceptions, creating a serious challenge for the
medical community and policymakers.  
This paper examines the scientific basis for
removing existing federal restrictions on nee-
dle exchange programs.
2The research shows that needle exchange pro-
grams can effectively and dramatically reduce
the number of Americans who become infected
with hepatitis and HIV.  The programs help
meet the health and humanitarian goals of help-
ing people who are already dealing with sub-
stance abuse problems avoid contracting and
transmitting these serious, life-altering diseases.  
A major U.S. policy goal should be to prevent
and reduce drug use.  Enough resources
should be devoted to treat drug abuse and
help individuals quit.
In addition to providing drug abuse treat-
ment, support must be provided to protect in-
dividuals who are struggling with drug abuse
from contracting hepatitis B and C and HIV.
Currently, “injection” drug users are at high
risk for these diseases, because they often end
up sharing needles when clean needles are
not available, and sharing needles is one of
the ways these illnesses can be spread.  Public
health officials designed “needle exchange”
programs, where drug users can exchange
used needles for clean ones so the disease is
not passed on from one drug user to another,
to help control the spread of these diseases.  
By helping prevent the spread of disease, it in-
creases the odds that a person struggling with
drug abuse can be helped, because it is sig-
nificantly harder to treat people for drug use
when their problems become compounded
by acquiring HIV or hepatitis B or C.  
Needle exchange programs have been en-
dorsed by leading scientific organizations and
individuals, including the Institute of Medicine
(IOM); the World Health Organization
(WHO); the American Academy of Pediatrics
(AAP); the American Medical Association
(AMA); the American Nurses Association
(ANA); the American Public Health Associa-
tion (APHA): Anthony Fauci, director of the
National Institute of Allergy and Infectious Dis-
eases; Julie Gerberding, former director of the
U.S. Centers for Disease Control and Preven-
tion (CDC); Donna E. Shalala, former secretary
of Health and Human Services; David Satcher,
former assistant secretary for health and sur-
geon general; and Harold Varmus, former 
director of the National Institutes of Health.15, 16  
Alternative approaches to needle exchange,
such as disinfection and decontamination and
outlawing the sale of needles, have been shown
to be much less effective.17 Many needle ex-
change programs often also work to target the
underlying problems of drug use by providing
and/or referring individuals to substance abuse
treatment and other health and social services.
Injection drug users account for one-fifth of
the 1.0 to 1.2 million Americans living with
HIV/AIDS and most of the hepatitis C
infections in the United States, according to
estimates from CDC.18 AIDS is the number
one cause of death among injecting drug
users.19 Injection drug users currently account
for 12 percent of all new HIV infections,
according to a 2009 report from the CDC.20
Nearly 32 percent of injecting-drug users
report sharing needles.21 As of November
2007, at least 185 syringe exchange programs
were operational in 36 states, District of
Columbia and Puerto Rico.22  
I.  SCIENCE SAYS NEEDLE EXCHANGE EFFECTIVELY
REDUCES RATES OF DISEASE 
THERE IS NO LONGER DOUBT THAT [NEEDLE EXCHANGE] PROGRAMS WORK, 
YET THERE IS A STRIKING DISJUNCTION BETWEEN WHAT SCIENCE DICTATES AND
WHAT POLICY DELIVERS.      13
-- NATIONAL INSTITUTES OF HEALTH (NIH) CONSENSUS MEETING
CLEARLY NEEDLE EXCHANGE PROGRAMS WORK. THERE IS NO DOUBT ABOUT THAT.     14
-- ANTHONY S. FAUCI, DIRECTOR, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
“
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3Some have worried that needle exchange
programs could promote increased drug
use or create the perception that the gov-
ernment is supporting illegal drug use.  The
programs are controversial and federal
funding to support needle exchange has
been banned for more than 20 years, since
1988.23 Only an act of Congress can over-
turn the ban.  A number of state and local
health departments continue to fund and
sustain these programs in many communi-
ties.  To address potential concerns, a num-
ber of communities have placed some
restrictions on the programs, such as pro-
hibiting them from being located near
schools, parks, and churches.  
While the programs are politically contro-
versial, hundreds of scientific studies have
been conducted that have found needle ex-
change programs can help to reduce HIV
transmission and do not promote illegal
drug use.  There is also evidence that needle
exchange programs do not increase unsafe
disposal of unused syringes among partici-
pants in these programs.24
2. NEEDLE EXCHANGE PROGRAMS DO NOT PROMOTE DRUG USE
SCIENCE: REDUCING DISEASE RATES WITHOUT INCREASING DRUG USE
A wide range of domestic and international research on needle
exchange has found that needle exchange programs significantly
reduce rates of disease and do not lead to increased drug use.  
In 2008, CDC concluded that the incidence of HIV among in-
jection drug users had decreased by 80 percent in the United
States in part due to needle exchange programs: “those ex-
posed [to HIV] through injecting drug use have reduced needle
sharing by using sterile syringes available through needle ex-
change programs or pharmacies and have reduced the number
of individuals with whom they share needles.”25
Some of the most prominent studies include:  
 A National Institutes of Health (NIH) Consensus Confer-
ence:  A consensus panel of non-governmental scientific experts
convened by NIH in February 1997 reviewed hundreds of scien-
tific studies and heard presentations by 15 researchers.   The
panel strongly endorsed the use of needle exchange programs to
curb the AIDS epidemic in the United States.26 The experts
concluded that the scientific evidence was clear that behavioral
intervention programs such as needle exchange were successful,
and did not increase illicit drug use among current drug users,
did not increase the number of drug users, and did not increase
the amount of discarded drug paraphernalia.27 The group issued
a strong recommendation in favor of removing government re-
strictions on needle exchange programs, and urged that phar-
macy sales of sterile injecting equipment become legal.28
 A Review by the Surgeon General: In March 2000, U.S. Sur-
geon General David Satcher, prepared an analysis of all peer-re-
viewed scientific studies of syringe exchange programs that had
been conducted since 1998.  This review concluded that needle
exchange programs are sound public health interventions that
reduce HIV transmission and do not promote illegal drug use.29
An Analysis by the World Health Organization (WHO):
In 2004, WHO, the Joint UN Programme on HIV/AIDS (UN-
AIDS), and the United Nations Office on Drugs and Crime, an-
alyzed more than 200 studies and found  “compelling”
evidence that increasing the availability and use of sterile inject-
ing equipment “contributes substantially to reductions in the
rate of HIV transmission.”30 In addition, the report said, there
was “no convincing evidence of major unintended negative
consequences...such as initiation of injecting among people
who have not injected previously, or an increase in the dura-
tion or frequency of illicit drug use or drug injection.”31 WHO
concluded that “the international experience across countries
and regions is so convincing that there is no longer any real jus-
tification for ... small-scale [pilot] programs.”32
The report cited a study published in 2002 that compared HIV
rates in 103 cities in 24 countries, which found that the HIV in-
fection rate declined by an average of 18.6 percent annually in
36 cities with needle exchange programs.  It increased by an
average of 8.1 percent annually in 67 cities without such pro-
grams.33, 34 Other research has reached similar conclusions.
For instance, a 1997 study compared HIV infection rates
among injecting drug users in 52 cities without syringe ex-
change programs, and 29 cities with needle and syringe pro-
grams in North and South America, Europe, Asia and the
South Pacific. On average, the HIV infection rate increased by
5.9 percent per year in the former and decreased by 5.8 per-
cent among the latter, according to the WHO report. 
 The report found limited evidence to support the efficacy of
disinfection and decontamination approaches, an alternative
prevention strategy promoted by U.S. public health officials
in the absence of federal support for needle exchange.
WHO recommended these approaches should only serve as
temporary measures when it was not possible to establish
needle exchange.35 The global health organization concluded
that paraphernalia laws were “barriers” to HIV control, and
that pharmacy-based programs and vending machines that
increase availability to syringes -- while useful -- were not as
effective as face-to-face contact via exchange programs.
They found that face-to-face programs also allowed for addi-
tional services, such as education, recruitment into drug
treatment, and access to primary care medical treatment.  
4According to the WHO:  “Communities or countries threatened by or experiencing an
epidemic of HIV infection among injecting drug users should urgently adopt measures to
increase the availability and utilization of sterile injecting equipment and to dispose of used
equipment. They should provide risk-reduction education, referrals to drug-dependence
treatment and abscess management, promote condom use, HIV testing and counseling,
and provide care, treatment and support for persons with HIV/AIDS and treatment of sex-
ually transmitted infections. If necessary, legislation related to drug dependence and drug
paraphernalia should be reviewed and amended in order to allow for and promote the im-
plementation of needle and syringe programmes.”36
ELIMINATING PROGRAMS HAS ADVERSE EFFECTS
One case study in Windham, Connecticut found that following the closure of the commu-
nity’s needle exchange, “significant increases were found in the percentage of respondents
who reported an unreliable source as their primary source of syringes, in respondents’ re-
ports of the frequency of reusing syringes, and in the percentage of respondents who re-
ported sharing of syringes. Surveys of outdoor drug-use areas found that the closure of the
needle exchange did not reduce the volume of discarded syringes and other drug-injection
debris.  The problems in Windham that led to the closure of the exchange still remain[ed],
and the city’s drug injectors [we]re engaging in higher levels of HIV risk behavior.”43
CASE STUDY IN NEW YORK
“[Needle exchange] programs...have been effective in reducing both incidence and prevalence
rates by 75 percent in New York City. The HIV epidemic in injecting drug users in New York
City has been the largest HIV epidemic in injecting drug users in the world. HIV was
introduced into the injecting drug population in New York City during the mid-1970s and it
spread very rapidly during the late 1970s and early 1980s. Substantial risk reduction efforts
began with injecting drug users in New York City during the mid-1980s, and HIV prevalence
stabilized at approximately 50 percent among this population. The legalization and large-scale
expansion of syringe exchange programs which began in 1992, the provision of HIV
prevention, testing, and counseling services, and the implementation of community outreach
and peer outreach interventions were associated with drastic reductions in HIV prevalence and
incidence rates. These declines were seen in multiple studies, including injecting drug users
recruited from drug detoxification programs, methadone maintenance programs, and through
street outreach. HIV prevalence among injecting drug users declined from approximately 50
percent in 1990 to the current level of 15 percent to 20 percent and HIV incidence declined
from an estimated 4/100 person-years at risk to an estimated 1/100 person-years.”42
 A 2006 Review of the International Evidence: A study published in 2006 reviewed a
wide range of the international evidence regarding the efficacy of syringe exchange pro-
grams.37 The authors concluded that there was “compelling evidence” that access to sterile
syringes “reduces HIV infection substantially,” and that there was “no convincing evidence of
any major unintended consequences,” such as an increase in illicit drug use.38 Furthermore,
the researchers found that needle exchange programs were cost-effective and provided ad-
ditional benefits, apart from reducing HIV infection, saying: “There is reasonable evidence
the [needle exchange programs] can increase recruitment into drug user treatment and pos-
sibly also into primary health care.”39 As with all previous reviews, the researchers stressed
that needle exchange programs by themselves were not enough to control HIV infection
among injecting drug users and should be part of a comprehensive prevention approach.
 A U.S. Department of Health and Human Services Report to Congress.  A 1997 
report to Congress by the U.S. Department of Health and Human Services (HHS) concluded
that syringe exchange programs were a valuable part of a comprehensive strategy to prevent
the transmission of infectious diseases, chief among them HIV.41
“Given consistent evidence
that multi-component HIV
prevention programs that
include sterile needle and
syringe is associated with
reductions in drug-related
HIV risk behavior, such
programs should be
implemented where
feasible.”40
-- Board on Global Health,
Institute of Medicine 2006
5“True, we found that addicts who took part in needle exchange programs in Vancouver
and Montreal had higher HIV rates than addicts who did not. That’s not surprising. Be-
cause these programs are in inner-city neighborhoods, they serve users who are at great-
est risk of infection. Those who didn’t accept free needles often didn’t need them since
they could afford to buy syringes in drugstores. They also were less likely to engage in the
riskiest activities. 
Also, needle exchange programs must be tailored to local conditions. For example, in
Montreal and Vancouver, cocaine injection is a major source of HIV transmission. Some
users inject the drug up to 40 times a day. At that rate, we have calculated that the two
cities we studied would each need 10 million clean needles a year to prevent the re-use of
syringes. Currently, the Vancouver program exchanges two million syringes annually, and
Montreal, half a million.”
--Julie Bruneau and Martin T. Schecter, writing for the New York Times, op-ed page about
their 1977 study in Vancouver and Montreal.44
Other Studies:  A few studies have raised doubts about the impact of needle exchange
programs.  However, the authors of one of the most widely cited studies which was conducted
in Vancouver and Montreal in 1977, argue that their work has been misinterpreted.  They found
that HIV rates were higher for a set of drug users who participated in needle exchange
programs, but also could purchase syringes in pharmacies.  The researchers concluded that
because these drug users could also purchase needles directly and that study was focused on
inner-city users where injection drug use is particularly high, it was not possible to evaluate the
impact of the needle exchange programs on HIV transmission based on their study.
A syringe costs less than one dollar,46 “compared to the $25,000-$30,000 a year for treat-
ing somebody for hepatitis C. But you really can’t put a dollar value on people whose lives
have been saved because they didn’t get an infectious disease.”47
--Bernard Lieving, Former Harm Reduction Program Manager for the New Mexico 
Department of Health 
RETURN ON INVESTMENT: HEPATITIS AND HIV PREVENTION SAVES
LIVES AND MONEY
A number of studies have shown syringe exchange programs to be cost-effective and money 
saving, particularly for HIV.45 In the United States, Medicaid covers HIV-related treatment costs for
many injecting drug users, so HIV prevention can save significant taxpayer dollars. Those with late-
stage liver disease as a result of hepatitis B or C also often become dependent on Medicaid.
One 1997 analysis estimated that between 4,394 and 9,666 cases of AIDS infection could
have been avoided in the United States, if syringe exchange programs had been established
during the early days of the epidemic.48 Researchers calculated the cost to the U.S. health
system at between $244-538 million.49
 Another study using mathematical modeling to calculate potential savings resulting from the
work of syringe exchange programs estimated that 100 percent coverage of sterile syringes
for a hypothetical one million injecting drug users in the United States would require 954.8
million needles at a cost of $423 million, and prevent 12,350 HIV cases and $1.3 billion in
treatment costs.50 A policy of funding comprehensive syringe exchange programs would
cost about $423 million for one year, with one-third of these costs paid as out-of-pocket ex-
penditures by drug users who purchased needles in pharmacies.  This would cost about
$34,278 for each HIV infection prevented -- considerably less than the estimate lifetime
costs of medical coverage for HIV, about $108,469.  
6 Another study predicted that needle exchange programs could prevent HIV infections among
clients, their sex partners and children at a cost of about $13,000 per infection.51 A study con-
ducted in Ontario, Canada conservatively predicted that the program would prevent 24 cases
of HIV infection over five years, thereby providing a savings of $1.3 million after the program
expenses were taken into account.52 A study conducted in New York found seven needle ex-
change programs exchanged 1,667,682 syringes in a year with an annual cost of $1,822,426,
and resulted in preventing 87 infections, saving $7.6 million in HIV treatment costs.53
 A cost-effectiveness study of needle exchange programs in Svetlogorsk in Belarus evaluated
a comprehensive strategy that included syringe exchange, safe sex counseling, condom pro-
motion, bleach distribution, and referrals for sexually transmitted disease services. The esti-
mated cost per each prevented HIV infection was only $68, notably cost effective.54 This is
considered to be a significant study because it confirms that needle exchange programs are
cost-effective even in a “resource-poor” setting.55
A few studies have looked at the financial impact of needle exchange programs regarding the
costs associated with hepatitis C.  However, at least one review of the existing scientific literature
predicted that the combined effect of needle exchange programs on all viruses’ transmission
would be larger than that of HIV alone, and that current research, by failing to include hepatitis C,
may have underestimated the overall cost-effectiveness of syringe exchange programs.56
An Australian study, which looked at the impact of syringe exchange programs on both HIV
and hepatitis C between 1991, when needle exchange became well established in the country,
and 2000, found that the government’s investment in syringe exchange programs produced
substantial financial benefits and cost savings.57 During that period, Australia spent a total of
$150 million on syringe exchange programs.  This included $130 million by the government,
the remainder by consumers.  During that time, the government estimated that 25,000 cases
of HIV were prevented, at a savings of $7 billion for lifetime treatment.  For hepatitis C, the
government estimated that 21,000 cases were prevented and that it saved about $783 million
in total treatment costs over the lifetime of cases.  Overall, total treatment costs saved by pre-
venting cases of HIV and HCV totaled approximately $7.8 billion.  The report pointed out that
including hepatitis C increases the return because no additional investments are required.
7A ban on the use of federal funds for needle
exchange programs has been in effect since
1988 out of concern that they could have the
inadvertent consequence of promoting drug
use, despite the evidence that these programs
reduce disease without increasing drug use.  
Ten years ago, in 1998, the Clinton Admin-
istration convened federal experts to evalu-
ate the research and reassess the policy.
Nine leading public health officials signed a
unanimous memorandum to then-Secretary
of HHS Donna Shalala finding there was
“conclusive scientific evidence that needle
exchange programs, as part of a compre-
hensive HIV prevention strategic, are effec-
tive public health interventions that reduce
the transmission of HIV and do not encour-
age the use of illegal drugs.”58 The nine of-
ficials included: 
 David Satcher, assistant secretary for health
and surgeon general, Department of Health and
Human Services; 
 Harold Varmus, director, National Institutes
of Health; 
 Claire Broome, acting director, Centers for Dis-
ease Control and Prevention; 
 Anthony Fauci, director, National Institute of
Allergy and Infectious Diseases; 
 Helene Gayle, director, National Center for
HIV, STD and TB Prevention, CDC; 
Margaret Hamburg, assistant secretary for
planning and evaluation, Department of Health
and Human Services; 
 Nelba Chavez, administrator, Substance Abuse
and Mental Health Services Administration; 
 Eric P. Goosby, director, Office of HIV/AIDS Pol-
icy, Department of Health and Human Services;
and 
 Alan I. Leshner, director, National Institute
on Drug Abuse.
Despite the scientific consensus, the adminis-
tration was concerned about political pressures
and potential negative perceptions, and left the
federal funding restrictions in place.  Former
President Bill Clinton has since expressed re-
gret for not removing the restrictions, stating
in 2002 at the XIV International AIDS Confer-
ence “I was wrong.”59 He said in a Frontline in-
terview in 2008 that at the time he felt that
“politically, the country wasn’t ready for it.”60
The U.S. Surgeon General from 1998 to 2002
David Satcher said he “had the responsibility
to communicate directly with the American
people.  So [he] chose to speak out about the
efficacy of needle exchange programs, and
[he] went around the country doing that and
many localities decided to fund these pro-
grams, despite the absence of federal fund-
ing.”61 In 2007 he testified before the U.S.
Congressional House Committee on Over-
sight and Reform that “the White House had
decided not to support federal funding for
needle exchange programs, despite the sci-
ence, because of a political environment in
Washington that would not support it.”62
Anthony Fauci, director, National Institute of
Allergy and Infectious Diseases, also testified
before Congress in support of needle ex-
change programs about the science support-
ing how the programs are effective for
reducing disease transmission rates without
leading to increased drug use.63
3.  BACKGROUND ON NEEDLE EXCHANGE POLICY
Exchange between Representative John Tierney (D-MA), and
Anthony Fauci, director of the National Institute of Allergy and
Infectious Diseases, during a September 16, 2008 hearing before
the House Committee on Oversight and Government Reform.
Tierney: So, Dr. Fauci, let me start with you, if I could. In your
professional scientific judgment, does the public health evidence
support the federal ban on funding needle exchange programs?
Fauci: No, it doesn’t. Actually, I was part of a group that I
helped co-chair years and years ago to look in a somewhat
meta-analysis way of all the data that you referred to asking the
two questions: A, does needle exchange help promote illicit
drug use? And, B, does it impede or block in many respects the
transmission of HIV? And the answers to both of those ques-
tions were: It doesn’t increase the injection drug use, and it
does prevent HIV infection. So the scientific data are really
rather firm and totally convincing that injection drug use and
the transmission of HIV through injection drug use can be de-
creased significantly by needle exchange programs.
8Laws and regulations enacted in many cities
and states make possession of needles a
crime, which creates barriers to obtaining
sterile needles legally and creating regulatory
hurdles for needle exchange programs.
Among these are: drug paraphernalia laws,
syringe prescription laws, pharmacy regula-
tions and practice guidelines, and restrictions
that often are imposed on syringe exchange
programs themselves. This creates a paradox:
injecting drug users are advised to use only
sterile syringes, but, at the same time, they are
unable to purchase or acquire sterile needles. 
Drug paraphernalia laws establish criminal
penalties for the manufacture, sale, distribu-
tion, possession, or advertisement of any item
used to produce and use illegal drugs, includ-
ing syringes.  In 2002, at least 47 states, the Dis-
trict of Columbia and the Virgin Islands had
such laws.64 Syringe prescription laws, which
prohibit dispensing or possessing syringes with-
out a valid medical prescription, were in effect
in eight states and one territory in 2002.65 A
2000 analysis showed that it was illegal for a
physician to prescribe sterile syringes to inject-
ing drug users in 46 states.66 Finally, as part of
their oversight responsibilities, state boards of
pharmacy develop and enforce regulations and
guidelines that cover many issues related to the
sale of syringes. These include display, adver-
tising, record-keeping, customer identification
and assessment of customers’ probable use.67
For examples of some state or local pro-
grams, see Appendix A.
Overview of State and Local Policies
“Syringe exchange programs were shown to be effective [in re-
ducing the spread of HIV] in the mid-to-late 1990s, and nothing
much has changed in that regard. The one thing that has changed
substantially, particularly in the United States, is that they have
become multi-service organizations. They not only address HIV,
but hepatitis C, abscesses, overdoses, and drug treatment,
among other things. Preventing HIV is obviously important, but it
is only one of many important functions they provide.”68
-- DON DES JARLAIS, Director of Research for the Baron Edmond
de Rothschild Chemical Dependency Institute at Beth Israel
Medical Center, New York
“Because most syringe and harm reduction programs that
work have mobile outreach vans, they are able to reach mar-
ginalized populations -- not only people who have substance
use issues, but who aren’t able to access other services. The
trust that syringe exchange staff builds with these people
over time significantly increases the likelihood that these oth-
erwise underserved people will actually access care -- not
just drug treatment, but all kinds of health services on a pre-
ventive basis, rather than in an emergency room.”69
-- KANDY FEREE, President and Chief Executive Officer of the
National AIDS Fund
POLICY APPROACH:  PROGRAMS CAN ALSO PROVIDE SUBSTANCE ABUSE AND DISEASE TREATMENT
Syringe exchange programs are an effective way to find hard-
to-reach drug users and connect them with a wide range of
important health and social services. They provide referrals to
substance abuse treatment and other social and medical serv-
ices. Some offer HIV/AIDS education and counseling, condom
distribution, on-site testing for HIV, hepatitis B, hepatitis C,
and tuberculosis, and instruction on how to prevent abscesses
and other bacterial infections. 
DISPARITIES IN INFECTIONS
Racial and ethnic minorities are disproportionately affected by
HIV/AIDS.  Of AIDS cases diagnosed in 2006, 49 percent were
African Americans, 19 percent were Hispanics, and 30 percent
were whites.70 
African Americans accounted for 45 percent of new HIV
infections diagnosed in the United States in 2006, even though
they comprised only 12 percent of the population.71 The HIV
infection rate among African Americans is seven times higher
than the rate among whites.  The infection rate among Latinos
is three times higher than the rate among whites.72
These disparities are also reflected in rates of transmission
from injection drug use.  Twenty-two percent of AIDS cases
among African-American men and 22 percent among Hispanic
men occurred through injection drug use, compared with 11
percent among white men.73
94. BACKGROUND ON DISEASE TRANSMISSION AND 
NEEDLE EXCHANGE PROGRAMS
NEEDLE EXCHANGE FAQ
How Does Needle Sharing Transmit Disease?
Transmission of blood-borne diseases, including HIV and hepatitis, can occur:
 Directly when an infected drug user shares a syringe;
 Indirectly when an infected injector shares injection equipment, such as water, cookers, cot-
ton, and spoons; or 
When drug users jointly prepare and share drugs with others.
Why Do Drug Users Use Dirty Needles?
A typical intravenous drug user injects about 1,000 times a year.74 Drug users are often unable
to buy sterile needles at a pharmacy due to cost or laws that prohibited them from buying drug
paraphernalia in many states.  Additionally, the social stigma of purchasing syringes stops others
from purchasing needles.  
Drug users then find other ways to obtain needles, such as sharing with other users, finding
needles previously used by diabetics, or purchasing them illegally from street dealers, who
often resell used needles.  
How Do Needle Exchange Programs Work?
Syringe exchange programs operate in different settings, including health and substance abuse
treatment clinics, storefronts, vans, and sidewalk tables. The requirements of how many
syringes can be exchanged and the circumstances under which these exchanges occur also
vary. Some programs are limited in the number of needles they can exchange; others require
clients to carry a special registration card in order to participate.  Many programs require a
“one-for-one” exchange.  For examples of needle exchange programs, see Appendix A.
HEPATITIS C VIRUS (HCV) INFECTION
Hepatitis C is a contagious liver disease that ranges in severity from a mild illness lasting a few
weeks to a serious, lifelong illness. It results from infection with the hepatitis C virus (HCV),
which is spread primarily through contact with the blood of an infected person. Hepatitis C
can be either “acute” or “chronic.” 
Acute hepatitis C virus infection is a short-term illness that occurs within the first six months
after someone is exposed to the hepatitis C virus. Approximately 75 to 85 percent of people
who become infected with hepatitis C virus develop chronic infection. 
Chronic hepatitis C virus infection is a long-term illness that occurs when the hepatitis C
virus remains in a person’s body. HCV can last a lifetime and lead to serious liver problems, in-
cluding cirrhosis (scarring of the liver) or liver cancer.   Chronic hepatitis C, for example, can
cause liver damage, liver failure, liver cancer, and death.
Globally, 200 million people, or more than three percent of the world’s population are infected
with HCV.75 CDC estimates that 3.2 million Americans have chronic HCV infection.76
10
HIV/AIDS
HIV is the virus that causes AIDS.  CDC defines AIDS to mean the later stages of when a per-
son’s immune system is severely damaged, marked by the presence of HIV infection as shown
by a positive HIV-antibody test plus at least one of the following:  the development of an op-
portunistic infection -- an infection that occurs when a person’s immune system is impaired,
such as Pneumocystis carinii pneumonia (PCP), or a CD4 lymphocyte count of 200 or less (a
normal count ranges from 800 to 1,200).  Some early symptoms of HIV can include: swollen
lymph nodes, diarrhea, weight loss, fever, and cough and shortness of breath.  Some later
symptoms of HIV/AIDS can include:  persistent fatigue, soaking night sweats, shaking chills or
fever higher than 100 F (38 C) for several weeks, swelling of lymph nodes for more than three
months, chronic diarrhea, persistent headaches, persistent white spots or unusual lesions on
the tongue or mouth, and blurred and distorted vision.  
Globally, nearly 33 million people were reported to be living with HIV.77 An estimated 1.0 to
1.2 million Americans are living with HIV/AIDS.  Nearly 30 years after emerging as a deadly
infectious disease, there is still no vaccine or cure for HIV.  A combination of pharmaceutical
interventions, when used correctly, can mitigate the effects of the disease and allow individuals
infected to live many years with HIV.
GLOBAL PERSPECTIVE
Worldwide, as of 2006, only eight percent of injecting drug users had access to HIV prevention
programs, including syringe exchanges.78 More than 40 countries operate needle and syringe
programs, including, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czech Repub-
lic, Denmark, El Salvador, Estonia, Finland, Germany, Greece, Hungary, India, Kazakhstan,
Latvia, Luxembourg, Nepal, Netherlands, Norway, Philippines, Poland, Portugal, Slovak Repub-
lic, Slovenia, Thailand, Ukraine and the United Kingdom.79 
Authorities in many developing countries have resisted establishing syringe exchange programs,
based on concerns they could be viewed as undermining the global commitment against illegal
drug use.80  
Although injecting drug use has been a longtime problem within developed nations, 78 percent
of the world’s estimated 13 million injecting drug users now live in developing countries.  Ten
percent of global infections and 30 percent of infections outside of sub-Saharan Africa are
attributed to injecting drug use.  Unsafe injections are the most common cause of hepatitis C
infection in developing countries, causing two million new infections each year and accounting
for 42 percent of cases.81
“HIV is under control among injecting drug users in Australia,” according to Alex Wodak,
director of St. Vincent’s Hospital Alcohol and Drug Service in Sydney, who has spent more
than two decades providing care to drug users in Australia, and initiated an unsanctioned
syringe exchange program there in 1986.82 Needle exchange services exist in every state
and territory in Australia, providing nearly 20 million syringes a year.
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The science supporting the public health
value of needle exchange in preventing
deadly and costly infectious diseases is com-
pelling and overwhelming.  Needle exchange
programs must be considered an integral part
of U.S. drug control policies.  Overall, the U.S.
must improve drug control policies and drug
abuse treatment.  One important aspect of
treating drug abuse is to ensure that people
who are drug users do not also contract seri-
ous diseases that create increased hurdles for
trying to treat them.  The evidence also clearly
shows that needle exchange programs do not
result in increased illegal drug use.  TFAH
strongly recommends that U.S. policy makers
embrace the science by lifting the ban on use
of federal funds for needle exchange pro-
grams.  This is critical for two reasons: (1) it
will free up important resources to support
life-saving interventions; and (2) it will de-stig-
matize existing programs and people.
We recommend that the following steps be
taken:
1.  Congress should remove the ban on use of
federal funds for needle exchange pro-
grams as part of consideration of the FY
2010 appropriations bill.  The ban has been
a recurring “rider” on the Labor, Health
and Human Services, Education and Re-
lated Agencies appropriations bill since
1988; by omitting it during the next appro-
priations cycle, Congress will effectively re-
peal the ban.  As part of its 2010 budget
submission, the Obama administration
should specifically recommend removal of
the ban, throwing the weight of the federal
government’s public health agencies be-
hind the science. A more affirmative mes-
sage could be sent through Congressional
passage of legislation permanently lifting
the ban.  Legislation to that effect was in-
troduced in the 110th Congress by Repre-
sentative José Serrano of New York (D) and
is expected to be reintroduced in 2009.
2.  Removal of the ban is only the first step in
assuring that needle exchange programs
are widely available to those at risk for
HIV, hepatitis C and other blood-borne
diseases.  CDC, the Surgeon General, and
the Substance Abuse and Mental Health
Services Administration should:
 Actively encourage use of HIV prevention
dollars and substance abuse block grant
funds for syringe exchange programs;
 Assure technical assistance to communities
and programs wishing to undertake syringe
exchange programs with federal dollars.  Be-
cause these programs have been stigmatized
and often run “underground” there is not a
standard set of best practices or technical as-
sistance programs available for those com-
munities wanting to adopt this intervention.
 Jointly educate mayors, governors, public
safety officials, and the drug treatment
community about the scientific value of
syringe exchange programs -- to overcome
years of inaccurate messaging.
Undertake a social marketing campaign in-
forming the public and those at risk of the
value of needle exchange programs -- so they
will be welcomed and used as an effective
public health intervention against HIV, 
hepatitis C, and other blood-borne diseases.
3.  As the Obama administration and the
Congress develop prevention interventions
in the context of health reform, they should
assure that clinicians can prescribe syringes
for the purpose of preventing infections
and that associated costs are covered as
part of a preventive benefit. 
5.  RECOMMENDATIONS
12
Currently, there are more than 40 syringe ex-
change programs operating in the state.83 The
California Department of Public Health plans
to provide a total of $2.25 million in funding
over the next three years to 10 programs.
Among 24 California syringe exchange pro-
grams evaluated between 2001 and 2003, 
83 percent also provided onsite HIV testing
and counseling, and all sites offered safe sex
and safe injection information, first aid, and
referrals for substance abuse treatment.
Among 560 program participants who were
interviewed for a survey, 76 percent received
medical and preventive care exclusively
through needle exchange programs.84 This
is important because syringe exchange pro-
grams are often the only health care
providers injecting drug users ever see. This
study, however, did not collect data from in-
jecting drug users who did not use syringe
exchange programs, so it was not possible to
compare efficacy.85 A number of studies,
however, have found that more generous sy-
ringe dispensing results in a lower risk of
transmission among program clients.86
In an earlier study conducted before pro-
grams in the state became legal, researchers
studying a San Francisco syringe exchange
program during a five-year period found that
the program did not encourage drug use, ei-
ther by recruiting new injecting drug users,
or by increasing drug use among current
drug users.87 In fact, injection frequency de-
creased from 1.9 injections per day to 0.7,
and the percentage of new injecting drug
users in the community dropped from three
percent to one percent.
In California, local governments must au-
thorize needle exchange programs before
they can operate.88 The law provides that
staff members for authorized programs be
exempt from arrest for possession or distri-
bution of drug paraphernalia laws, but there
is no such protection for injecting drug
users.89 In a survey of 935 individuals who
visited authorized syringe exchange pro-
grams between 2001 and 2003, 17 percent re-
ported being arrested or receiving a citation
for drug paraphernalia possession in the pre-
ceding six months.90
In 2005,  laws took effect that allow phar-
macies to provide 10 or fewer syringes to
adults without a prescription, and for adults
to possess 10 or few syringes from an au-
thorized source, including syringe exchange
programs.  However, like the needle ex-
change programs, only local governments
can approve these exemptions -- and they
apply only to those specific jurisdictions.
That means possessing 10 or fewer syringes
may be legal in one town and illegal in the
neighboring town.
APPENDIX A:  EXAMPLES OF STATE, LOCAL, AND
PHILANTHROPIC INITIATIVES
A.  California
Local and state health departments, sub-
stance abuse treatment facilities, HIV clinics,
health philanthropies and other foundations
have found creative ways to establish and/or
financially support needle exchange pro-
grams in the absence of federal funding.
Some programs function openly, with au-
thorization; others, believing they must re-
spond to the public health urgency regard-
less of the law, operate “underground.”  For
unauthorized programs, law enforcement of-
ficials often are either unaware of these ac-
tivities or ignore them.
13
The cumulative number of AIDS cases
(3,458) in Delaware was 0.4 percent of all re-
ported U.S. cases in 2005.91 Delaware ranks
33rd among states in the total cumulative
number of reported AIDS cases and, despite
being the second smallest state in the United
States, had the seventh highest incidence of
new AIDS cases in 2005.
In July 2006, the state legislature approved a
five-year pilot needle exchange program lim-
ited to the city of Wilmington.  It is the only
program in Delaware, and is restricted to city
residents.  The state authorized Brandywine
Counseling, a long-established substance
abuse treatment center, to administer the pro-
gram.  Now in its second year, the program has
received $200,000 for each of its first two years
of operation.  It requires a one-for-one needle
exchange, and serves injecting drug users ages
14 and older.  The program must be mobile,
meaning that needles cannot be distributed
from stationary or office sites, and rotates
among eight different locations in the city. 
There are 336 participants enrolled in the
Wilmington program, which exchanged 9,677
needles between February 1, 2007 and Sep-
tember 15, 2008.  Participants receive a mem-
bership card, which protects them from legal
action under the state’s paraphernalia law, and
allows them to exchange needles. There are
no names or photographs on the cards, only a
unique identifier linking them to the program.
B.  Wilmington, Delaware 
New Mexico has adopted what is believed to
be the nation’s most comprehensive harm 
reduction program.  In 1997, the state legisla-
ture approved needle exchange coverage
throughout the state.  About 15 community-
based organizations and 40 public health 
offices provide needle exchange and other
services. During its ten years, the program 
has collected and dispersed almost ten million
syringes.  The state also funds primary medical
care and other services for those who use the
program.  To be sure, the prevalence of HIV in
New Mexico is relatively low -- the state reports
only about 150 new cases every year -- but cases
among injecting drug  users dropped from 26
in 1998 to five in 2007.94 There is not enough
data yet about lowering hepatitis C infections,
which are a bigger problem in the state, with
an estimated 3,500 new cases annually.
D.  New Mexico
The District of Columbia has the highest rate of
new AIDS cases in the country; an estimated
one of every 20 residents of the city is living with
HIV.92 PreventionWorks! began in October
1998 in order to provide needle exchange and
other harm reduction services in the District of
Columbia. The program incorporated as a non-
profit organization after Congress passed legis-
lation that same year forbidding both the
District from using its local funds to support
needle exchange services, and private organi-
zations that receive any federal funds from op-
erating needle exchange, even if funded with
private donations.  Federal lawmakers repealed
the ban in late 2007.  Within days, D.C. Mayor
Adrian M. Fenty announced $650,000 in Dis-
trict funding for needle exchange, including
$300,000 for PreventionWorks!93 
The program dispenses clean needles and ac-
cepts dirty ones two afternoons a week from
its office on 14th Street, and runs a mobile
unit that visits nine sites near active drug
strips five days a week, Tuesday through Sat-
urday, with repeated visits to target locations.
The program also plans to establish a neigh-
borhood harm reduction center with ex-
panded hours and clinic services. 
In 2007, PreventionWorks! served an esti-
mated 1,851 participants with education, re-
ferrals and sterile needles. This included
exchanging and disposing of nearly 180,000
sterile syringes. The program also made
nearly 500 drug treatment referrals. 
C.  District of Columbia
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In November 2001, the Allegheny County
Board of Health declared a public health
emergency with regard to HIV and hepatitis
C, effectively making needle exchange legal
in the county. Allegheny County has an esti-
mated 12,000 injecting drug users, and in-
jecting drug use is the second leading risk
factor for HIV. Data from the Pittsburgh ex-
change site between July 2003 and January
2005 showed that almost half of those who re-
quested hepatitis C screening tested positive.96
Prevention Point Pittsburgh is the only legal
needle exchange program in the southwest-
ern part of Pennsylvania.  The Pittsburgh
program runs two needle exchange sites, one
at the local health department, also the site
of overdose prevention classes/naloxone dis-
tribution, and also from an unmarked white
van in the Hill District, where the program
originally began. Prevention Point Pittsburgh
serves about 200 injecting drug users each
week. In 2007, the program exchanged ap-
proximately 330,000 needles.
Prevention Point Pittsburgh relies solely on in-
dividual donations and grants from area foun-
dations as the Maurice Falk Medical Fund,
Three Rivers Community Foundation, Jewish
Health Care Foundation, Staunton Farm
Foundation and the Birmingham Foundation.
Pennsylvania bars the use of state money for
needle exchange and the city does not fund
the program either.  The city and state support
the organization’s other programs, including
HIV and hepatitis C prevention education,
condom distribution, overdose prevention,
and referrals to other health services, such as
primary and mental health care, and drug
treatment.  The program also runs an innova-
tive overdose prevention/education training
in the county jails - - because inmates upon re-
lease are vulnerable to severe overdose reac-
tions due to their reduced drug tolerance. 
E.  Pittsburgh, Pennsylvania
CASE STUDY:  CHIMAYO, NEW MEXICO
“When we ask someone when they first ‘used,’ they often will respond that they were
given drugs at their 13th birthday party by an uncle.”
-- MARTIN WALKER, Director of Adult Health Services, for the Santa Fe Mountain Center.
In Chimayo, a small village located in Rio Arriba County, north of Santa Fe in the north central
part of the state, there are staggering rates of opiate addiction.  County-wide, overdose rates are
three times the national average.95 The county also has higher than national average rates of
hepatitis C, due to needle sharing among injecting drug users.  The Santa Fe Mountain Center
provides numerous health services to try to curb drug addition and reduce related diseases,
including harm reduction counseling, basic wound care, condom distribution, prevention
information on HIV, hepatitis A, B, and C; HIV counseling and testing, community information 
and referrals, and food distribution.  They also provide needle exchange and conduct overdose
prevention classes, which teach drug users how to identify an overdose, perform rescue
breathing, and safely administer naloxone. A nurse, who rides in the mobile van, has the authority
to dispense naloxone, obtained via a doctor’s prescription. 
The program budget, most of which comes from state funds, is $130,000 for fiscal 2009.  The
program enrolls participants using a unique identifier, and serves everyone who has an enroll-
ment card, including those who live outside the area. The well-publicized program, which op-
erates from a van, works four shifts a week, Monday through Thursday. Each shift lasts six
hours. This past year, the Chimayo area program exchanged 240,000 syringes. 
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The AIDS Resource Center of Wisconsin is
one of the largest and most comprehensive
AIDS service agencies in the country. It pro-
vides numerous health and social services to
more than 3,000 state residents living with
HIV. It also offers an array of AIDS preven-
tion services, including needle exchange
programs that operate in 11 Wisconsin cities:
Milwaukee, Racine, Kenosha, Beloit, Apple-
ton, Green Bay, Wausau, Au Claire, Superior,
La Crosse and Madison. In 2007, the needle
exchange program in all cities combined had
14,300 exchanges (transactions), totaling
775,000 needles.
Needle exchange began here in 1994. Since
then, the program has seen a 66 percent de-
crease in HIV infection among injecting
drug users.
Known as “Lifepoint,” the program began with
needle exchange, but later expanded to include
HIV prevention education and risk reduction
counseling, HIV and hepatitis C counseling and
testing, and referrals for drug treatment and
other social services. The Milwaukee program
makes about 150 drug treatment referrals a year,
and also provides intensive outpatient treatment
to about 70 individuals. 
The program’s fleet of vans visits more than
20 exchange sites at community locations
convenient to participants. In Milwaukee,
the program also uses several ‘satellite’ sites,
which are locations where organizations,
such as churches and community health cen-
ters, are willing to conduct exchanges.
The state health department’s AIDS program
provides $200,000 a year for the center’s nee-
dle exchange program.  The program also
receives about $310,000 from private foun-
dations, as well as an additional $200,000
from local fund raising efforts.  
F.  Wisconsin
EXAMPLES OF PHILANTHROPIC EFFORTS
Because there is no federal money available for syringe exchange programs, and state and local
dollars can be scarce and unpredictable, numerous philanthropies have stepped in to support
programs.  Some examples include:
Syringe Access Fund
The Syringe Access Fund was created in 2004 to respond to the deadly connection between
injection drug use and HIV. A grant-making collaboration among several philanthropies, the Sy-
ringe Access Fund has reviewed 353 proposals and awarded 148 grants totaling more than
$4.4 million in 26 states, the District of Columbia, and Puerto Rico since 2004.97
National AIDS Fund
The National AIDS Fund, one of the founding partners of the Syringe Access Fund, has been sup-
porting syringe exchange since the earliest days of such programs. Many needle exchange programs
were seed-funded with support from the National AIDS Fund and its Community Partnerships, a
network of grassroots AIDS/HIV organizations. In 2007, the National AIDS Fund and its Community
Partnerships awarded more than $500,000 in grants to support syringe exchange.
AIDS Foundation of Chicago
The AIDS Foundation of Chicago, founded in 1985 by community activists and physicians, collabo-
rates with community groups to develop and improve HIV/AIDS services, fund and coordinate
prevention, care, and advocacy projects; and works for effective, compassionate HIV/AIDS policy.
The foundation supports at least seven needle exchange programs in the Cook County area. In fis-
cal 2009, it will distribute an estimated $529,500 to support harm reduction programs in the area.
The foundation also conducts outreach to pharmacies to promote implementation of the non-pre-
scription syringe purchasing law, a state measure which allows persons older than 18 to buy up to
20 syringes without a prescription. Finally, the group runs a program that provides free “sharps”
[disposal] containers to pharmacies so injecting drug users can safely dispose of used needles.
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